Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Conditions
Schizophrenia
Interventions
Risperidone, Placebo, LY2140023
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Escondido, California • Garden Grove, California • Paramount, California + 16 more
Completed Phase 3 Interventional Results available

A Physical Dependence Study in Schizophrenia

NCT01452919
Conditions
Schizophrenia
Interventions
LY2140023, Placebo
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Oakland, California • San Diego, California • Torrance, California + 5 more
Terminated Phase 3 Interventional Results available

A Study of LY2140023 in Patients With Schizophrenia

NCT01307800
Conditions
Schizophrenia
Interventions
LY2140023, Placebo
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Wichita, Kansas
Conditions
Schizophrenia
Interventions
LY2140023, Placebo, Standard of Care
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
Completed Phase 1 Interventional Results available

Glutamate Reducing Interventions in Schizophrenia

NCT03321617
Conditions
Clinical High Risk for Psychosis
Interventions
Pomaglumetad methionil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Schizophrenic Disorders
Interventions
LY2140023, Placebo, Moxifloxacin
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Garden Grove, California • San Diego, California • North Miami, Florida + 5 more
Conditions
Schizophrenia
Interventions
Pomaglumetad methionil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 33 more
Conditions
Schizophrenia
Interventions
LY2140023, Aripiprazole
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
32
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 29 more
Conditions
Schizophrenia
Interventions
LY2140023, Aripiprazole
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Garden Grove, California • Glendale, California
Conditions
Schizophrenia
Interventions
LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Conditions
Methamphetamine Use Disorder
Interventions
Pomaglumetad methionil, Placebo, Methamphetamine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Completed Phase 1 Interventional Accepts healthy volunteers

Pomaglumetad Effects on Glutamate Biomarkers

NCT02919774
Conditions
Healthy Controls
Interventions
POMA, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • New York, New York